📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). (2015)

First Author: Fervenza FC

Attributed to: Understanding the autoimmune mechanism in idiopathic membranous nephropathy (IMN) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1159/000430849

PubMed Identifier: 26087670

Publication URI: http://europepmc.org/abstract/MED/26087670

Type: Journal Article/Review

Volume: 130

Parent Publication: Nephron

Issue: 3

ISSN: 1660-8151